Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tigemocoxib SCHEMBL2736424 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| Tigemocoxib SCHEMBL30656575 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| Tigemocoxib SCHEMBL29528190 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| Tigemocoxib SCHEMBL5171872 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| Tigemocoxib SCHEMBL30656557 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| Tigemocoxib SCHEMBL15845458 | 0.99 | PTGS2 (0.97) | PTGS2PTGS1 | |
| Tigemocoxib SCHEMBL15845456 | 0.99 | PTGS2 (0.97) | PTGS2PTGS1 | |
| SCHEMBL5645595 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL17858788 | 0.90 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL16893912 | 0.90 | PTGS2 (0.81) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113330004-B | Differential solubility driven asymmetric conversion process for substituted 2H-chromene-3-carboxylic acids | 株式会社AskAt | 2023-11-17 | — | — | CN | claimed |
| EP-3906232-B1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | ASKAT INC (JP) | 2023-05-10 | — | — | EP | claimed |
| US-11555023-B2 | Process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids | ASKAT INC. (JP) | 2023-01-17 | — | — | US | claimed |
| CN-110292575-B | Pharmaceutical composition | 株式会社AskAt | 2022-05-13 | — | — | CN | claimed |
| US-20220144792-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | ASKAT INC. (JP) | 2022-05-12 | — | — | US | claimed |
| EP-3906232-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | AskAt Inc. (JP) | 2021-11-10 | — | — | EP | claimed |
| CN-113330004-A | Differential solubility driven asymmetric transformation process for substituted 2H-chromene-3-carboxylic acids | 株式会社AskAt | 2021-08-31 | — | — | CN | claimed |
| EP-2769718-B1 | MEDICINAL COMPOSITION | ASKAT INC (JP) | 2021-03-17 | — | — | EP | claimed |
| WO-2020153279-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | ASKAT INC. (JP) | 2020-07-30 | — | — | WO | claimed |
| EP-2938607-B1 | SALTS AND CRYSTAL FORMS OF A COX-2 INHIBITOR | ASKAT INC (JP) | 2018-09-12 | — | — | EP | claimed |
| WO-2003015797-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND GLUCOSAMINE | PHARMACIA CORPORATION (US) | 2003-02-27 | — | — | WO | claimed |
| WO-2002096516-A1 | USE OF COMPOSITIONS COMPRISING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS IN COMBINATION WITH RADIATION FOR INHIBITION OR PREVENTION OF CARDIOVASCULAR DISEASE | PHARMACIA CORPORATION (US) | 2002-12-05 | — | — | WO | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| WO-2002078626-A2 | THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS | PHARMACIA CORPORATION (US) | 2002-10-10 | — | — | WO | claimed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | claimed |
| US-20020077328-A1 | Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain | PHARMACIA CORPORATION | 2002-06-20 | — | — | US | claimed |
| WO-2002005799-A2 | COMBINATION OF A COX-2 INHIBITOR AND A VASOMODULATOR FOR TREATING PAIN AND HEADACHE PAIN | PHARMACIA CORPORATION (US) | 2002-01-24 | — | — | WO | claimed |
| US-6034256-A | CYCLOOXYGEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-03-07 | — | — | US | claimed |
| EP-0977748-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047890-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-10-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555023-B2 | Process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids | UACA, SLC7A1, CDYL | PTGS2 3076/4885PTGS1 4536/4885 |
| US-20020077328-A1 | Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain | PTGIR, VASP, TRPV2 | PTGS2 4/4885PTGS1 8/4885 |
| US-20220144792-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | UACA, SLC7A1, CDYL | PTGS2 3076/4885PTGS1 4536/4885 |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | PTGS2 4/4885PTGS1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.